Artificial Intelligence

As restaurants face economic headwinds, a new AI platform is empowering servers, enhancing guest experience, and promising to double bottom-line profits.

Independent 2025 endpoint security tests expose the top performers and true costs, offering CISOs a clear guide to navigating a complex market.

NUS scientists unveil a microneedle patch for plants, slashing waste and boosting growth. A new investment frontier in high-end, sustainable agriculture.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?

A landmark report reveals corporate commitment to women's advancement is plummeting, creating an ambition gap that threatens to erase a decade of progress.

A top global forum warns of politicized trade and tech divides. How will this impact pharma supply chains, AI in medicine, and market access?

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

WEP's deployment of 700 inspection systems in Missouri showcases its execution, but can it leverage this win in a competitive multi-billion dollar market?